Drug Profile


Alternative Names: TAK-385

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator Takeda
  • Developer Takeda; Takeda Oncology
  • Class Antineoplastics; Ketones; Pyrimidines; Small molecules
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pain; Uterine leiomyoma
  • Phase II Endometriosis; Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 16 Nov 2016 Myovant Sciences plans three phase III trials in Uterine leiomyoma, Pain and Prostate cancer
  • 07 Oct 2016 Efficacy and adverse events data from a phase II trial in Prostate cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Jun 2016 Relugolix licensed to Myovant worldwide (except Japan and certain other Asian countries)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top